SCHEMBL1763583

SCHEMBL1763583

Cc1ccc(S(=O)(=O)CC2CCCN2C(=O)OC(C)(C)C)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
APP P05067 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
DRD2 P14416 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
SLC6A2 P23975 1/20 0.45
HRH2 P25021 1/20 0.45
HTR1D P28221 1/20 0.45
HTR1B P28222 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR7 P34969 1/20 0.45
DRD3 P35462 1/20 0.45
OPRK1 P41145 1/20 0.45
HTR2B P41595 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1763578 1.00 LMNA (0.47) LMNANPSR1KMT2AMEN1APP
SCHEMBL17394232 0.90 FPR3 (0.49) LMNANPSR1KMT2AMEN1APP
SCHEMBL17394233 0.90 FPR3 (0.49) LMNANPSR1KMT2AMEN1APP
SCHEMBL17928085 0.89 LMNA (0.47) LMNANPSR1KMT2AMEN1APP
SCHEMBL143674 0.86 LMNA (0.47) LMNANPSR1KMT2AMEN1APP
SCHEMBL345625 0.86 LMNA (0.47) LMNANPSR1KMT2AMEN1APP
SCHEMBL86666 0.86 LMNA (0.47) LMNANPSR1KMT2AMEN1APP
SCHEMBL28890890 0.86 ALDH1A1 (0.44) LMNANPSR1KMT2AMEN1NPC1
SCHEMBL7413885 0.85 LMNA (0.46) LMNANPSR1KMT2AMEN1APP
SCHEMBL5253351 0.85 NPC1 (0.43) LMNANPSR1KMT2AMEN1APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118315-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118315-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 LMNA 2110/4885NPSR1 4409/4885KMT2A 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.